Montelukast vs Zafirlukast — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Leukotriene Receptor Antagonist

Montelukast

Brand: SINGULAIR

First FDA approval: 2012-02-28

Leukotriene Receptor Antagonist

Zafirlukast

First FDA approval: 2010-11-18

Lowest NADACAcquisition cost floor across all NDCs

$0.043Per unit

$0.508Per unit

Average NADACAcross all dosage forms and strengths

$0.473Up to $9.27

$0.590Up to $0.645

Generic manufacturersActive ANDA holders — FDA Orange Book

2046 total ANDAs filed

48 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$222.8MFull year

$10.2MFull year

Part D claims (CY24)Total fills, all strengths

18.7M5.9M beneficiaries

100K29K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$12Per claim, all NDCs

$102Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

NoneClear

Generic availableFDA Orange Book

Yes20 manufacturers

Yes4 manufacturers